SEC Form SC 13G filed by AnaptysBio Inc.

7/10/24 10:10:35 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ANAB alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ANAPTYSBIO INC COMMON STOCK Cusip #032724106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #032724106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,869,767 Item 6: 0 Item 7: 2,870,618 Item 8: 0 Item 9: 2,870,618 Item 11: 10.507% Item 12: HC Cusip #032724106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,870,618 Item 8: 0 Item 9: 2,870,618 Item 11: 10.507% Item 12: IN Item 1(a). Name of Issuer: ANAPTYSBIO INC Item 1(b). Address of Issuer's Principal Executive Offices: 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO, CA 92121 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 032724106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,870,618 (b) Percent of Class: 10.507% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,870,618 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ANAPTYSBIO INC. No one other person's interest in the COMMON STOCK of ANAPTYSBIO INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. July 9, 2024 Date /s/ Richard Bourgelas Signature Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on July 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ANAPTYSBIO INC at June 28, 2024. FMR LLC By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Get the next $ANAB alert in real time by email

Recent Analyst Ratings for

$ANAB

Date	Price Target	Rating	Analyst
2/4/2025	$25.00	Outperform	Wolfe Research
12/11/2024	$52.00 → $19.00	Buy → Neutral	H.C. Wainwright
12/2/2024		Buy → Neutral	BTIG Research
7/22/2024	$55.00	Buy	H.C. Wainwright
7/19/2024	$29.00 → $69.00	Neutral → Overweight	JP Morgan
4/16/2024	$47.00	Outperform	Leerink Partners
4/11/2024	$56.00	Overweight	Wells Fargo
3/12/2024	$20.00 → $34.00	Neutral → Outperform	Wedbush

More analyst ratings

SEC Form SC 13G filed by AnaptysBio Inc.

Chat with this insight

Recent Analyst Ratings for
$ANAB

$ANAB
Press Releases

Fastest customizable press release news feed in the world

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Participation in March Investor Conferences

$ANAB
Leadership Updates

Live Leadership Updates

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Actym Therapeutics Appoints Thomas Smart as CEO

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

$ANAB
SEC Filings

AnaptysBio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-K filed by AnaptysBio Inc.

AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ANAB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ANAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ANAB
Financials

Live finance-specific insights

$ANAB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ANAB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Wolfe Research initiated coverage on AnaptysBio with a new price target

AnaptysBio downgraded by H.C. Wainwright with a new price target

AnaptysBio downgraded by BTIG Research

Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

SEC Form SC 13G filed by AnaptysBio Inc.

Chat with this insight

Recent Analyst Ratings for $ANAB

$ANAB Press Releases

Fastest customizable press release news feed in the world

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Participation in March Investor Conferences

$ANAB Leadership Updates

Live Leadership Updates

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Actym Therapeutics Appoints Thomas Smart as CEO

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

$ANAB SEC Filings

AnaptysBio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-K filed by AnaptysBio Inc.

AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ANAB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ANAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ANAB Financials

Live finance-specific insights

$ANAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ANAB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Wolfe Research initiated coverage on AnaptysBio with a new price target

AnaptysBio downgraded by H.C. Wainwright with a new price target

AnaptysBio downgraded by BTIG Research

Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

Recent Analyst Ratings for
$ANAB

$ANAB
Press Releases

$ANAB
Leadership Updates

$ANAB
SEC Filings

$ANAB
Analyst Ratings

$ANAB
Insider Trading

$ANAB
Financials

$ANAB
Large Ownership Changes

$ANAB
Insider Purchases